On 14 April 2020, Johnson & Johnson reported its first-quarter results for the three months ended 31 March 2020. Company sales in the first quarter totalled $20.69 billion, an increase of 3.3% (1Q2019: $20.02 billion). Adjusted earnings per share increased by 9.5% to $2.30 per share (1Q2019: $2.1 per share). The Consumer segment contributed 17.52% to sales, Pharmaceuticals contributed 53.81%, and the Medical Devices segment contributed the remaining 28.67%.
Johnson & Johnson may face headwinds due to the impact of the COVID-19 pandemic, economic factors such as interest rate and exchange rate fluctuations, competition, and ongoing litigation risk.
Click here to download the full PDF report.